Blocking Patent Focus Of Acorda's Fed. Circ. MS Drug Appeal
Acorda urged a Federal Circuit panel Thursday to revive four patents covering its flagship product, the multiple sclerosis drug Ampyra, in oral arguments focusing heavily on whether a "blocking patent" held by another company was...To view the full article, register now.
Already a subscriber? Click here to view full article